StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report published on Monday morning. The firm issued a sell rating on the stock. OCX has been the topic of a ...

EDT OncoCyte (OCX) files to sell 10.61M shares of common stock for holdersDon't Miss Our End of Quarter Offers: Discover the latest ...

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July ...

Fintel reports that on March 28, 2025, Lake Street initiated coverage of OncoCyte (NasdaqCM:OCX) with a Buy recommendation.

Q4 2024 Earnings Call Transcript March 24, 2025 OncoCyte Corporation misses on earnings expectations. Reported EPS is ...

OncoCyte Corp (OCX) advances with new product launches and strategic alliances, while navigating regulatory hurdles and competitive pressures.

OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. The company had revenue of $1.49 million during the quarter, compared to analysts’ expectations of $0. ...

Oncocyte Corp. reports Q4 2024 revenue of $1.5 million, launching a new transplant assay and securing strategic partnerships. Oncocyte Corp. reported a revenue of $1.5 million for Q4 2024 and a ...

OncoCyte plans to expand its clinical trial to include approximately six U.S. centers and additional European sites, enrolling 150 matched samples to demonstrate assay efficacy. Future updates ...

Oncocyte is at a pivotal stage in commercializing what we expect to be an industry-transforming organ transplant rejection monitoring test. We aim to deliver proven, more affordable, faster tests ...

As of March 19, 2025, the average one-year price target for OncoCyte is 4.12 GBX/share. The forecasts range from a low of 3.96 GBX to a high of 4.37 GBX. The average price target represents an ...

March 24, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its fourth quarter ...